ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 999

Cost Consideration For Biologics For Patients With Rheumatoid Arthritis In a Pharmacy Benefit Management Setting

Ning Wu1, Yuan-Chi Lee2, Neel Shah3 and David J. Harrison3, 1Economic Analysis and Solutions, United BioSource Corporation, Lexington, MA, 2United BioSource Corporation, Lexington, MA, 3Amgen Inc., Thousand Oaks, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: etanercept and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Of the seven biologics FDA-approved for the treatment of moderate to severe rheumatoid arthritis (RA) as of August 2011, etanercept, adalimumab, certolizumab, and golimumab were subcutaneously (SC) administered; abatacept, infliximab, and rituximab were intravenous (IV) infusions. Utilization of these agents is often controlled by Pharmacy Benefits Managers (PBMs) using various methods which can affect dosing in clinical practice, gaps in therapy, treatment persistence and switching, and in turn the costs.  This study describes the annual cost of biologics per treated patient with RA using administrative claims from a PBM.

Methods: The Medco Database was used to identify adults (18-63 years) with a claim for etanercept, adalimumab, infliximab, abatacept, rituximab, golimumab, or certolizumab between July 1, 2008 and August 31, 2011 preceded by ≥180-days of enrollment. The first claim for biologics was used to define the index agent and date. Patients had to be continuously enrolled for ≥360 days post-index and have a diagnosis of RA between 180 days before and 30 days after the index date. Patients with other conditions for which some of these agents are indicated (e.g. psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, non-Hodgkin’s lymphoma, or chronic lymphocytic lymphoma) were excluded. Annual cost per treated patient equaled total dose for the index biologic and all other biologics taken in the post-index period multiplied by wholesale acquisition cost (WAC) as of June 1, 2013, plus the costs associated with administrations, calculated as number of infusions multiplied by the 2013 Medicare Physician Fee Schedule costs. 

Results:

In the 4,736 patients with RA in this study, etanercept (40.3%), adalimumab (27.9%), and infliximab (19.0%) were the most frequently prescribed biologics followed by abatacept (7.1%), rituximab (3.7%), golimumab (1.2%), and certolizumab (0.7%). Mean age was 51.2 years (SD 9.1) and 78.5% were female. Among the three most commonly prescribed biologics, the annual cost per treated patient was lowest for patients on etanercept ($21,706), followed by infliximab ($22,030) and adalimumab ($23,150). Among the other agents, cost per treated patient was highest for certolizumab ($21,630), followed by golimumab ($20,526), abatacept ($17,386), and rituximab ($16,571).

Conclusion:

Of the three most frequently prescribed biologics for RA, the annual cost per treated patient was the lowest for etanercept.  Cost may be an additional consideration when choosing biologic treatments for RA.


Disclosure:

N. Wu,

Amgen Inc,

9;

Y. C. Lee,

Amgen,

9;

N. Shah,

Amgen Inc.,

1,

Amgen Inc,

3;

D. J. Harrison,

Amgen Inc.,

1,

Amgen Inc.,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cost-consideration-for-biologics-for-patients-with-rheumatoid-arthritis-in-a-pharmacy-benefit-management-setting/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology